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Background: Chronic pain arising from degenerative diseases of the joint such as osteoarthritis (OA) has a strong
peripheral component which is likely to be mediator driven. Current treatments which reduce the production of
such mediators i.e. non-steroidal anti-inflammatory drugs (NSAIDs), can help to lessen pain in OA patients. However,
this is not always the case and complete pain relief is rarely achieved, suggesting that additional unidentified mediators
play a role. Here we have investigated the notion that chemokines might act as such pain mediators in OA.
Results: Using the monosodium iodoacetate (MIA) model of chronic joint pain the expression of over 90 different
inflammatory mediators, mainly cytokines and chemokines, were measured in tissues taken from the femorotibial joint
(cartilage, subchondral bone, fat pad) using custom-made quantitative real-time polymerase chain reaction (qPCR) array
cards. At both the day 3 and 14 time points, numerous inflammatory mediators were significantly up-regulated in these
tissues, although it was clear that the largest transcriptional dysregulation occurred in the cartilage. Using individual
qPCR to measure immune cell markers, a significant infiltration of macrophages was measured in the cartilage and fat
pad at day 3. Neutrophil infiltration was also measured in the fat pad at the same time point, but no infiltration
was observed at day 14. Combination of mRNA expression data from different time points and tissues identified
the chemokines, CCL2, 7 and 9 as being consistently up-regulated. The overall increase in CCL2 expression was
also measured at the protein level.
Conclusion: Chemokines in general and CCL2, 7 and 9 in particular, represent promising targets for further
studies into the identification of new pain mediators in chronic joint pain.
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The exact aetiology of osteoarthritis (OA) is still unclear,
but is likely driven by an over-active chondrocyte popu-
lation within the cartilage of the affected joint [1]. Eventu-
ally atypical chondrocytes favour a catabolic phenotype,
releasing many factors, such as cytokines and chemokines,
which can promote the degradation process by increasing
the production of matrix degrading enzymes [2-4]. Further
progression leads to the degradation of the articular cartil-
age as well as the underlying subchondral bone, with bouts
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reproduction in any medium, provided the orPain is the most common symptom of OA and often
used as a criterion for diagnosis. Interestingly, it seems
that there is a strong peripheral drive to the persistent
pain experienced by OA patients. For example, the intra-
articular injection of local anaesthetics can significantly
reduce pain scores [5] and the surgical removal of the
diseased joint often leads to the complete ablation of
pathological pain [5,6]. NSAIDs represent the first line
analgesic treatment and are effective when given topically
[7]. Therefore it is likely that pro-algesic mediators in the
periphery make a strong contribution. However, NSAIDs
are often unable to completely relieve OA pain [8], unlike
joint replacement where all putative peripheral pain me-
diators are removed, and such observations suggest add-
itional pain mediators have a role. For instance, recent
work has shown that the neutralisation of the pro-algesicLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Time course of primary pain-related hypersensitivity
in the MIA model. Significant primary pain-related hypersensitivity
in the MIA model, 3, 7 and 14 days post induction compared to
vehicle treated animals as measured by the percentage of weight
bearing asymmetry between ipsilateral and contralateral hind limbs.
Two-way repeated measures ANOVA, post hoc Tukey, **p < 0.01,
***p < 0.001; n = 6. All data are expressed as mean ± SEM.
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[9]. In addition prolonged NSAID use commonly causes
severe adverse effects [10] and therefore the identifica-
tion of unrecognised pain mediators might allow for the
development of more adequate pain therapies with re-
duced side-effect profiles.
Cytokines and chemokines have themselves been im-
plicated in modulating pain processing [11]. The periph-
eral application of members such as IL1β, TNFα, CCL2
and CXCL1 can induce pain-related behaviours in rodents
[12-14]. Since these same factors are present in the osteo-
arthritic joint, they represent an interesting group of poten-
tial pain mediators in OA.
The cartilage is a key tissue in the generation of in-
flammatory factors during OA [4]. Despite evidence
showing that the cartilage can become innervated during
joint degradation [15], this tissue is generally considered
to be aneural and therefore it is unclear as to how much
pro-algesic molecules produced here might contribute to
chronic joint pain. Other peri-articular tissues such as
the subchondral bone and synovium are highly inner-
vated [16,17], as well as the rarely considered infrapatel-
lar fat pad [18], and might represent more important
pain producing sites in OA.
Using the chemically-induced, monosodium iodoace-
tate (MIA) model of chronic joint pain, in which histo-
logical signs reflect some of those seen clinically [19-22],
the expression of both chemokines and cytokines have
been measured using custom-made qPCR array cards.
This was carried out in cartilage, subchondral bone and
fat pad, with the aim of identifying mediators which may
participate in driving OA pain.
Results
Time course of pain-related behaviour in the MIA model
Pain-related behaviour is a well-established feature of the
MIA model and has previously been demonstrated in a
number of species [22-25]. Weight bearing asymmetry is
considered a measure of primary pain-related behaviour in
the MIA model and is reduced by treatment with anal-
gesics such as NSAIDs [19,22,26,27]. Here, the presence
of such pain-like behaviour was confirmed after intra-
articular injection of 1 mg MIA (Figure 1). Figure 1 shows
a significant reduction in weight borne on the ipsilateral
limb in the MIA model at days 3, 7 and 14 when compared
to vehicle treated rats. The greatest deficient was measured
at day 3 with ipsilateral hind limb weight bearing in the
MIA model on average reduced to 50.7 ± 4.9%, compared
to 109.7 ± 3.6% in vehicle treated animals. The mean
weight borne on the ipsilateral hind limb increased at day
14 (68.7 ± 4.1%) but still remained highly significantly dif-
ferent when compared to control animals (98.5 ± 7.1%).
This data confirms the presence of primary pain-related
behaviour in the MIA model at both day 3 and 14.Regulation of inflammatory mediators in femorotibial
joint tissues from the MIA model
Using custom-made qPCR array cards the relative ex-
pression levels of 92 different target transcripts were
measured in the MIA model from cartilage, subchondral
bone and the infra-patellar fat pad, and compared to ve-
hicle treated rats at both day 3 and 14 post induction. It
should be noted that the subchondral bone samples used
for RNA extraction also contained the underlying bone
marrow. All qPCR array data from each time point and
tissue are shown in Additional file 1: Table S1. Data are
displayed as the mean fold change (FC) which is the
relative abundance of the transcript in the MIA model
in comparison to vehicle treated animals when setting
the level in these animals as 1.0. The range of one standard
deviation from this mean is shown in parenthesis. Of par-
ticular interest were those transcripts most up-regulated
that could potentially be driving the abnormal pain-like be-
haviours. A biological significance was arbitrarily defined
as a greater than 2 FC in the relative expression of the
transcript in MIA treated tissue when compared to the ex-
pression in control.
Gene expression changes: Day 3
Three days after injury a number of transcripts were
dysregulated in the cartilage, fat pad and subchondral
bone of the MIA model when compared to vehicle con-
trol animals. Table 1 shows the top twelve up-regulated
transcripts ranked in order of FC for the each tissue. In
the cartilage CCL21 (20.8 (4.0-108.2)) showed the greatest
fold increase compared to control, although this change
was not statistically significant. However, four genes in the
top twelve were significantly increased in the MIA model
Table 1 DAY 3: Top up-regulated inflammatory mediators in the MIA model
Rank Cartilage Subchondral bone Fat pad
Gene name FC Gene name FC Gene name FC
1 CCL21 20.8 (4.0-108.2) CCL17 5.7* (4.5-7.3) EREG 10.1 (2.8-36.3)
2 IL12B 13.9 (3.7-51.9) IL12b 5.4 (2.3-12.8) NRG1 7.4 (2.6-20.9)
3 CCL12 13.9* (6.0-31.9) BDNF 4.8 (1.8-13.1) AREG 7.0* (3.8-13.2)
4 EREG 8.3 (2.6-25.7) CCL7 4.7 (2.6-8.4) iNOS 5.0* (2.9-8.8)
5 CCL2 5.8 (2.7-12.6) CXCL11 4.3 (1.4-13.1) CXCL5 4.9* (3.2-7.6)
6 CCL7 5.8 (2.8-11.7) IL6 3.5 (1.0-12.0) GCSF 4.1 (1.7-10.1)
7 CXCL1 4.9 (2.3-10.2) CCL2 2.9 (1.7-5.0) IL11 3.8 (2.2-6.4)
8 XCL1 4.4** (3.8-5.1) CCL5 2.6 (1.6-4.2) CCL3 2.3 (−1.3-7.2)
9 CCL5 3.9* (2.9-5.4) EDN1 2.5 (1.2-4.9) ARTN 2.3 (1.6-3.3)
10 CXCL13 3.7 (1.3-10.3) ARTN 2.4 (1.4-4.4) LIF 2.1 (1.4-3.1)
11 IBA1 3.6* (2.8-4.6) CCL9 2.4* (1.9-3.0) NGF 1.9 (1.4-2.5)
12 CXCL2 3.5 (−1.3-15.1) CCL21 2.3 (−4.9-26.2) CXCL17 1.9 (−1.5-5.4)
*p<0.05, *p<0.01. CCL; chemokine (CC-motif) ligand. IL; Interleukin. EREG; Epiregulin. CXCL; chemokine (CXC-motif) ligand. XCL; chemokine (XC-motif) ligand. IBA1;
ionised calcium binding adaptor molecule 1. BDNF; Brain derived neurotrophic factor. EDN1; Endothelin 1 ARTN; Artemin. NRG1; Neuregulin 1. AREG; Amphiregulin. iNOS;
inducible nitric oxide. GCSF; Granulocyte colony stimulating factor. LIF; Leukemia inhibitory factor. NGF; Nerve growth factor.
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XCL1 (4.4 (3.8 – 5.1)) and CCL5 (3.9 (2.9 – 5.4)), and the
macrophage marker ionised calcium-binding adapter mol-
ecule 1 (IBA1) (3.6 (2.8 – 4.6)). As with the cartilage, all
genes in the top 12 for the subchondral bone data set
showed a greater than 2-fold increase in their expression.
Here the top up-regulated gene, CCL17 (5.7 (4.5-7.3)), was
of a smaller magnitude of increase when compared to the
top gene in cartilage, but was statistically significant versus
expression in the vehicle group. Another chemokine CCL9
(2.4 (1.9-3.0)) was also statistically significantly increased in
the subchondral bone at day 3. In the infrapatellar fat pad,
not all of the top 12 transcripts shown had a greater
than 2-fold increase in their expression following MIAFigure 2 Day 3: Distribution of inflammatory mediator expression in
expression in each tissue at day 3 in the MIA model. The data points show
order, starting from those most down-regulated (compared to control), to
not necessarily correspond to the same gene. The blue shaded box represe
as the mean FC, FC =MIA/Control, n = 92. (B) The percentage of genes > 2
of genes was up-regulated in the cartilage (42.5%) as compared to the subtreatment, unlike in the cartilage and bone. Still, there
were a number of significant changes in the fat pad and
these included the chemokine CXCL5 (4.9 (3.2-7.6)), in-
ducible nitric oxide synthase (iNOS, 5.0 (2.9-8.8)) and a
member of the epidermal growth factor receptor (EGFR)
ligand family, amphiregulin (AREG, 7.0 (3.8-13.2)).
To gain a better overall idea of inflammatory mediator
expression change in the MIA model at day 3, the distri-
bution of gene expression for each tissue is shown in
Figure 2A ranked in order of FC. Overall for each tissue
the majority of genes were not dysregulated by MIA injec-
tion at day 3 (blue shaded area). However, as highlighted in
Table 1, there were a group of genes in each tissue, which
were up-regulated when compared to control, although theeach tissue as ranked by FC. (A) The distribution profile of mediator
the mean FC for each individual transcript. These values are ranked in
those most up-regulated. Adjacent data points in different tissues do
nts an area of +/−2≤ FC. X-axis is on a log2 scale. Data are displayed
FC up-regulated in the each tissue. As shown, the greatest percentage
chondral bone (16.1%) and fat pad (10.8%).
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joint is comprised of many tissues which are affected dur-
ing OA disease, it is likely that they could all contribute to
the production of putative pain mediators. Therefore, the
identification of the principal mediator producing tissue
might be important from a pain perspective. In the sub-
chondral bone and fat pad up-regulated transcripts
amounted to 16.1% and 10.8%, respectively, of the total
genes measured (Figure 2B). This is in contrast to the car-
tilage where 42.5% of inflammatory mediator transcripts
were up-regulated. In addition, these genes were generally
of a greater magnitude of FC when compared to the other
tissues studied. Therefore in terms of inflammatory medi-
ator expression, the cartilage seems to be the main con-
tributor at day 3 in the MIA model. It should be noted
that a number of genes were also down-regulated, with
the majority seen in the fat pad.
Gene expression changes: Day 14
In the MIA model 14 days after induction, the same tran-
scripts were measured from the same femorotibial joint
tissues. Table 2 shows the top twelve up-regulated tran-
scripts ranked in order of FC for the each tissue. At day 14
it seems that of the top 12 transcripts, the majority were
significantly increased when compared to control levels. Of
particular interest were the three top up-regulated genes,
CCL7 (25.5 (12.1 – 53.8)), CCL2 (21.8 (12.9 – 37.0)) and
CCL9 (17.0 (12.5 – 23.0)). All of these were up-regulated
at day 3, but their magnitude of fold increase was much
greater 14 days after MIA injection. In addition, the che-
mokine CCL17 (10.5 (5.1 – 21.5)), the top ranked transcript
in the subchondral bone at day 3, was now significantly
up-regulated in the cartilage. The subchondral bone hadTable 2 DAY 14: Top up-regulated inflammatory mediators in
Rank Cartilage Su
Gene name FC Gene name
1 CCL7 25.5* (12.1-53.8) CCL9
2 CCL2 21.8** (12.9-37.0) CCL7
3 CCL9 17.0** (12.5-23.0) CCL22
4 EDN1 13.7 (5.1-37.2) CCL2
5 iNOS 11.4* (8.1-16.2) LIF
6 CCL17 10.5* (5.1-21.5) CCL17
7 AREG 8.1 (2.7-24.3) IL11
8 IL11 6.8 (3.7-12.5) KITLG
9 CXCL13 6.6 (2.4-18.3) iNOS
10 PTGES 5.8** (4.8-7.0) IL1A
11 CCL22 5.7* (3.4-9.4) ARTN
12 CCL12 5.0 (2.7-9.2) IL1B
*p<0.05, **p<0.01 CCL; chemokine (CC-motif) ligand. IL; Interleukin EDN1; Endothelin 1
ligand. PTGES; Prostaglandin E synthase. LIF; Leukemia inhibitory. KITLG; c-KIT ligand. Afewer genes up-regulated (only 8 of the top 12), although
the top genes were of a greater magnitude of change,
highlighted by CCL9 which was now significantly increased
by 10.8 (7.1-16.5) fold compared to control. Although
genes in the fat pad also showed a greater magnitude of
change, none of these were significant.
The distribution of gene expression for each tissue at
day 14 is shown in Figure 3A. Here there is a striking in-
crease in the expression of inflammatory mediators in
the cartilage when compared to the other tissues. With
the exception of the top up-regulated factor in the fat
pad, the increase in transcription is also of a much
greater magnitude in the cartilage. The profile of up-
regulated genes in the fat pad and subchondral bone
seem very similar and in comparison to day 3 the per-
centage of genes up-regulated was the same in the fat
pad, 10.8%, and slightly decreased in the bone to 9.7%
(Figure 3B). In contrast, the percentage of up-regulated
genes in the cartilage was clearly decreased to 24.7%
(Figure 3B). In line with expression changes measured at
day 3 in the MIA model, the greatest transcriptional up-
regulation seems to occur again in the cartilage. Al-
though the percentage of genes overexpressed was lower at
day 14 than at day 3, the magnitude of fold increase was
much greater.
Identifying putative pain mediators
From the data presented it is clear that the cartilage ex-
perienced the greatest transcriptional dysregulation at
both time points. It is, however, unclear as to what effect
time had on individual mediator expression. In terms of
recognizing putative pain mediators, it seems important
to identify those genes up-regulated at both day 3 andthe MIA model
bchondral bone Fat pad
FC Gene name FC
10.8* (7.1-16.5) BDNF 26.1 (11.1-61.4)
7.2 (1.6-31.6) iNOS 10.6 (2.7-40.8)
6.3 (3.2-12.6) CCL1 10.1 (2.3-44.0)
3.7 (2.2-6.1) IL3 4.0 (1.0-15.7)
3.6 (2.7-4.7) IL27B 4.0 (2.0-7.8)
2.9 (−1.1-9.1) CCL21 3.9 (1.9-8.2)
2.6 (1.1-6.5) AREG 3.8 (2.6-5.8)
2.2 (1.2-4.1) CXCL5 2.9 (1.6-5.4)
1.9 (1.2-3.1) IL1A 2.8 (−1.7-12.6)
1.9 (−1.0-3.7) CCL9 2.7 (1.7-42)
1.8 (1.1-3.0) NRG1 1.9 (−3.3-12.3)
1.7 (1.1-2.7) IL7 1.8 (−1.4-4.6)
. iNOS; inducible nitric oxide. AREG; Amphiregulin. CXCL; chemokine (CXC-motif)
RTN; Artemin. BDNF; Brain derived neurotrophic factor. NRG1; Neuregulin 1.
Figure 3 Day 14: Distribution of inflammatory mediator expression in each tissue as ranked by FC. (A) The distribution profile of
mediator expression in each tissue at day 14 in the MIA model. The data points show the mean FC for each individual transcript. These values are
ranked in order, starting from those most down-regulated (compared to control), to those most up-regulated. Adjacent data points in different
tissues do not necessarily correspond to the same gene. The blue shaded box represents an area of +/−2≤ FC. X-axis is on a log2 scale. Data are
displayed as the mean FC, FC =MIA/Control, n = 92. (B) The percentage of genes > 2 FC up-regulated in the each tissue. As shown, the greatest
percentage of genes was up-regulated in the cartilage (24.7%) as compared to the subchondral bone (9.7%) and fat pad (10.8%).
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associated with robust pain-related behaviour (Figure 1).
Figure 4 shows that the correlation of gene expression
for each tissue between day 3 and 14 occurred in a
positive and significant manner (Figure 4A-C, r = 0.227
p = 0.00743, r = 0.327 p = 0.00147, r = 0.283 p = 0.00629,
respectively). These correlations do imply that the same
mediators might be driving pain-like behaviours at both
time points. The red shaded area shows the genes with
a greater than 2-fold increase at both day 3 and 14. This re-
lated to 12 genes in the cartilage (Figure 4A), 3 in the fat
pad (Figure 4B) and 4 in the subchondral bone (Figure 4C).
These genes are listed in Table 3 and it is evident that the
majority are members of the chemokine family. It should
be noted that the genes consistently up-regulated in the
subchondral bone, were also up-regulated in the cartilage
at 3 and 14 days post MIA induction. This observation in-
dicates that the same mediators were also increased in dif-
ferent tissues. To combine tissue data at each time point a
combined ranking approach was used (see Methods) where
each gene received a combined rank value (CRV). Within
each data set genes were ranked by FC and received a rank
value depending on their position. These rank values were
then averaged to obtain a CRV. This approach allowed for
an accurate method for quantifying rank across data sets
and gave an idea of rank variability. The top ranked genes,
i.e. those genes that were consistently up-regulated across
tissues, are shown for both day 3 and 14 also in Table 3. At
day 3, 8 of the top 12 combined ranked genes were chemo-
kines and 7 of these were members of the same subfamily,
with CCL7 the overall top ranked gene. At day 14 the che-
mokine CCL9 was the top overall ranked gene. Here non-
chemokine transcripts make up half of the top combined
ranked factors, with iNOS being the second top ranked
gene at day 14. More bluntly, combined ranking was usedto combine all data sets and this is shown in the last col-
umn in Table 3. When all of these comparisons are consid-
ered it is easy to see that some genes were consistently
up-regulated across tissues and time points. For example,
iNOS was found in four of the comparisons made and
there is evidence to suggest that this enzyme, which is pri-
marily found in immune cells, has a role in pain processing
in general [28] and might even regulate OA pain [29]. In
contrast, the up-regulation of the pro-algesic factor CXCL5
[30] was restricted to the fat pad, suggesting that putative
OA pain mediators might be tissue constrained.
The identification of genes which should be targeted for
further investigation is important. An over-representation
in Table 3, i.e. an indication of consistent up-regulation, is
one way of recognising such factors. It seems obvious that
the chemokines CCL2, 7 and 9 fall into this category since
all three were listed amongst the top genes in 5 out of the
6 comparisons and were the top 3 ranked genes when all
data was combined. CCL2 has previously been implicated
in pain; however CCL7 and CCL9 represent novel targets.
Therefore these three chemokines seem to signify prom-
ising targets for the identification of putative pain medi-
ators in OA and using conventional qPCR the increased
mRNA expression of CCL2 and CCL9 has been validated
(Additional file 2).
However for these chemokines to truly be targets for
future studies into chronic joint pain it is important to
validate that the increase in mRNA is also seen at the
protein level as this may not always be the case [31].
Here we have used CCL2 as an exemplar. Using protein ly-
sates obtained from cartilage, subchondral bone and fat
pad at day 14 in the MIA model, the level of CCL2 was
compared against vehicle treated control tissue. Figure 5A
shows that, although not statistically significant, there is a
large increase in CCL2 protein 14 days after MIA injection
Figure 4 Correlation of inflammatory mediator expression
between day 3 and 14 in each femorotibial tissue. Day 3 and
day 14 gene expression was plotted against each other for the
cartilage (A), fat pad (B) and subchondral bone (C). For each tissue
there was a positive and significant correlation (A-C, r = 0.227
p = 0.00743, r = 0.327 p = 0.00147, r = 0.283 p = 0.00629, respectively).
By expressing the data this way, those factors which had a > 2 fold
increase at both time points could be identified (red shaded area). In
total there were 11 of these genes in the cartilage (A), 3 in the fat
pad (B) and 4 in the subchondral bone (C). Pearson’s correlation
coefficient, n = 92. Data is displayed as the mean FC, FC =MIA/Control.
Both axes on Log 2 scale.
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CCL2 protein in vehicle treated cartilage was just within
the range of detection and when normalised to 1 mg/ml of
the total protein loaded, the average amount was 0.7 ±
0.1 pg/ml. This is in contrast to MIA treated tissue where
the average normalised CCL2 protein level detected was
23.9 ± 16.5 pg/ml. For both the subchondral bone and fat
pad a significant increase in the level of CCL2 was mea-
sured from MIA treated animals versus control (Figure 5B
and C). The level of CCL2 in vehicle treated animals was
4.5 ± 0.9 and 2.9 ± 0.6 pg/ml for the subchondral bone and
fat pad respectively. This increased to 14.9 ± 2.5 pg/ml in
the subchondral bone and 7.8 ± 1.4 pg/ml in the fat pad
14 days after MIA treatment.
Immune cell infiltration in femorotibial joint tissues of the
MIA model
Chemokines play a pivotal role in the recruitment of
immune cells and the orchestration of the inflammatory
response, and many of these cell types have been impli-
cated in enhancing pain processing in the periphery
through the release of algogenic factors [32]. Therefore
cell recruitment is one possible mechanism by which
chemokines might contribute to OA pain. The first few
days of the MIA model are represented by an initial in-
flammatory phase [19,21]. Here, using qPCR to measure
the expression of the cell markers IBA1 and GCSFR for
macrophages and neutrophils respectively, immune cell
infiltration was seen in the MIA model at day 3 (Figure 6).
Although no significant increase in GCSFR expression
was seen in the cartilage (Figure 6A), a significant in-
crease in relative mRNA expression of IBA1 (1.8 ± 0.17)
compared to vehicle (1.0 ± 0.17, Figure 5D) was found. In
the fat pad both GCSFR (6.5 ± 1.5) and IBA1 (5.0 ± 1.0)
relative mRNA expression was significantly increased, in
agreement with previous literature [33], suggesting that
immune cells had infiltrated these tissues at day 3 in
the MIA model (Figure 6B, E) However, no significant
changes in the expression of either cell marker was found
in the subchondral bone (Figure 6C, F).
In the MIA model inflammation is lost by days 5 – 7
and by day 14 the model is thought to have entered a
non-inflammatory state. In agreement with this, there is
no difference in either GCSFR or IBA1 expression be-
tween vehicle and MIA treated animals at day 14 in any
tissue, suggesting that the infiltration of these immune
cells has subsided (Figure 7A-F).
Discussion
The aim of this study was to measure the expression of
inflammatory genes as possible mediators of chronic
joint pain in the MIA model. Using the femorotibial joint
tissues of cartilage, subchondral bone and fat pad, we
found that many of these factors, in particular chemokines,
Table 3 Top ranked mediators across different comparisons in the MIA model
Rank Greater than 2 FC Combined ranking
Cartilage Subchondral bone Fat pad Day 3 CRV (±SEM) Day 14 CRV (±SEM) Day 3 + 14 CRV (±SEM)
1 CCL2 CCL7 iNOS CCL7 83.0 (5.0) CCL9 88.3 (2.7) CCL7 85.0 (3.2)
2 CCL7 CCL17 AREG CCL5 81.3 (3.2) iNOS 87.7 (2.0) CCL2 83.3 (3.8)
3 CCL12 CCL2 CXCL5 CCL2 80.0 (7.0) CCL7 87.0 (4.5) CCL9 80.5 (5.3)
4 CCL9 CCL9 - CCL3 79.0 (2.9) CCL2 86.7 (3.4) ARTN 78.2 (2.4)
5 CXCL13 - - XCL1 78.3 (4.4) BDNF 80.7 (5.8) iNOS 77.8 (6.5)
6 CCL17 - - ARTN 78.0 (5.0) ARTN 78.3 (2.0) IL18 69.3 (3.9)
7 AREG - - IL6 77.0 (5.8) IL1A 78.3 (5.2) AREG 66.2 (12.8)
8 XCL1 - - EREG 76.3 (14.2) CCL22 78.0 (8.3) XCL1 65.5 (10.6)
9 CXCL2 - - CCL21 76.0 (11.0) CXCL16 72.3 (1.3) IBA1 65.2 (5.5)
10 IL18 - - CCL12 73.3 (11.6) IL18 72.0 (1.5) CCL21 64.7 (13.0)
11 ARTN - - PROK2 73.3 (4.2) CCL4 71.7 (3.2) CCL4 64.5 (6.9)
12 iNOS - - CCL9 72.7 (8.4) IL7 71.7 (5.0) BDNF 63.7 (13.2)
CRV = combined rank value. CCL; chemokine (CC-motif) ligand. AREG; Amphiregulin. XCL; chemokine (XC-motif) ligand IL; Interleukin. CXCL; chemokine (CXC-motif)
ligand. ARTN; Artemin. iNOS; inducible nitric oxide. EREG; Epiregulin. PROK2; Prokineticin 2. BDNF; Brain derived neurotrophic factor. IBA1; ionised calcium binding
adaptor molecule 1.
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related behaviours. Although tissues were individually
assessed, when data sets were evaluated it seemed that
some factors, such as CCL2, 7 and 9 were consistently
up-regulated, increasing the likelihood of them being
pain mediators in OA.
Initially, pain-related behaviour was measured 3, 7 and
14 days post MIA injection. In agreement with previous
reports, a significant ipsilateral weight bearing deficient
was measured at each time point [22,33]. This effect
peaked in the early inflammatory phase (day 3), consist-
ent with other studies [27,33]. It is notable that both the
intensity of pain-like behaviour and structural pathology
are dependent on the dose of MIA [27,34]. One, two
and three milligrams of MIA all produce robust pain-
like behaviours, which are generally more profound as
the dose is increased [19,20,34,35]. Activating transcrip-
tion factor 3 (ATF3) expression in DRG neurons, a marker
of peripheral nerve injury, is transiently expressed in theFigure 5 CCL2 protein expression at day 14 in the MIA model. The am
14 days after treatment in the cartilage (A), subchondral bone (B) and fat pad
although when compared to vehicle treated animals this was not statistically
subchondral bone (B) and fat pad (C). The protein concentration shown i
n = 6 (B and C). All data are expressed as mean ± SEM.1 mg MIA model [22]. However, the expression of ATF3
is more prominent and persistent following the injection
of 2 mg of MIA and in agreement with nerve damage hall-
marks there is a microgliosis in the corresponding area of
the spinal cord, as well as a reduction in intra-epidermal
nerve fibre density in the plantar hind paw skin [35,36].
Therefore the 1 mg MIA model, rather than being another
model of nerve injury, likely induces persistent pain as a
result of the degenerating joint. In addition, such as ob-
served in OA patients [5], pain in this model can be atten-
uated by the intra-articular injection of lidocaine [34],
suggesting that the abnormal sensory behaviour displayed
by MIA animals after 1 mg of the chemical originates
from joint tissues.
Following confirmation of pain-like behaviour, custom-
made qPCR arrays were used to measure the expression of
inflammatory mediators in the femorotibial joints at day 3
and 14. At day 3 the cartilage showed the largest transcrip-
tional change compared to the fat pad and subchondralount of CCL2 protein was measured in vehicle and MIA animals
(C). A large increase in CCL2 protein was measured in the cartilage (A)
significant. Significant increases in CCL2 protein was measured in the
s normalised to 1 mg/ml of total protein. T-test, **p < 0.01, n = 3 (A),
Figure 6 Day 3: Expression of immune cell markers in the MIA model. Relative changes in the transcript levels of GCSFR (A-C) and IBA (D-F)
were measured in the MIA model compared to vehicle controls. Here GCSFR and IBA were used to measure neutrophil and macrophage infiltration
respectively. No significant change was measured between MIA and controls in both cartilage (A) and the subchondral bone (C). However a significant
increase in GCSFR expression was measured in the fat pad of MIA treated animals (B). With IBA1 a significant increase in expression was measured in
the MIA group in both the cartilage (D) and fat pad (E). No difference was measured in the subchondral bone (F). T –Test (C, D-F), Mann–Whitney
Rank Sum Test (A-B), *p < 0.05; n = 4. All data are expressed as mean ± SEM.
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http://www.molecularpain.com/content/9/1/57bone. OA pathology is thought to be initiated in the cartil-
age and in the MIA model the chondrocytes are initially
targeted and undergo necrosis which is evident by day 1
[21]. Both cytokines and chemokines are involved in medi-
ating this process [3,4]. For example, the chemokine CCL5,
which was significantly up-regulated in the cartilage at day
3, has been shown to play a key role in the degradation of
this tissue by activating chondrocytes to produce matrix
metalloproteinases and other catabolic factors [37]. The
macrophage marker IBA1 was also significantly increased.
Therefore it is plausible to suggest that many inflammatory
mediators are over-expressed in the cartilage at this stage
either by atypical chondrocytes or by infiltrating immune
cells. Importantly however, the cartilage is aneural and
therefore pro-algesic mediators produced here would need
to act on peri-articular tissues to cause pain. This inflam-
matory process is also prominent in the fat pad, which
doubles in weight and is subjected to a significant mono-
cyte and neutrophil infiltration [33], which was also mea-
sured here. In accordance a number of inflammatory
mediators were up-regulated and included the chemokine
CXCL5, which can recruit both neutrophils and macro-
phages in vivo and cause mechanical hypersensitivity whengiven to naïve rats [30]. Although not typically considered
an important tissue in OA, the infrapatellar fat pad is
highly innervated by nociceptive fibres [18] and is also a
good source of cytokines and chemokines [38]. Interest-
ingly, it has been suggested that the fat pad is one of the
most pain-sensitive knee joint tissues in un-anaesthetised
subjects [39] and it is of note that in a small cohort of OA
sufferers 6 months after total joint replacement, more pa-
tients reported total pain relief if they also had the fat pad
removed [40]. Therefore mediators produced here might
be particularly important in causing OA pain. The degrad-
ation of the joint is also characterised by the remod-
elling of the underlying bone. Although histopathological
changes in this tissue at day 3 have not previously been
noted, we do find that on a transcriptional level, significant
changes do occur.
At day 14, similar to day 3, the cartilage again dis-
played the greatest change in terms of mediator expres-
sion compared to the other tissues. In the fat pad at this
stage no increase was measured for neutrophil or macro-
phage markers, in agreement with previous findings indi-
cating that inflammation and immune cell infiltrate
subside by day 14 [33]. Although inflammatory mediators
Figure 7 Day 14: Expression of immune cell markers in the MIA model. Relative changes in the transcript levels of GCSFR (A-C) and IBA (D-F)
were measured in the MIA model compared to vehicle controls. No significant change was measured between MIA and controls in cell markers at
both day 3 and 14 in all tissues (A-F). T –Test (B-F), Mann–Whitney Rank Sum Test (A), *p < 0.05; n = 4. All data are expressed as mean ± SEM.
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http://www.molecularpain.com/content/9/1/57were up-regulated, none of the changes were significant
when compared to vehicle treated animals. At this point
in the MIA model, the subchondral bone has begun to
undergo significant remodelling with obvious bone resorp-
tion [19,21,22]. Therefore it is surprising that fewer media-
tors were dysregulated in this tissue at day 14. It is
probable that a large transcriptional regulation is occurring
in the subchondral bone, potentially comprising genes not
measured by these qPCR array cards.
The aim of this study was to identify new putative pain
mediators in chronic joint pain. By combining data sets
the most prominently up-regulated genes were the che-
mokines CCL2, 7 and 9. In this study we have chosen to
concentrate on mRNA expression levels as a proxy to
estimate changes in protein levels, since this allows for
the accurate measurement of numerous factors from small
tissue samples. However an increase in mRNA does not
always directly correlate with an exact increase in protein
levels [31]. Here we measured a large and statistically sig-
nificant increase in CCL2 mRNA in the cartilage 14 days
after MIA injection. When looking at protein levels, again
a large increase was measured. However due to high vari-
ability in the MIA group this was not significant. CCL2 is
a secreted protein and as well as acting in the cartilage is
it likely released into the joint capsule. The rate of thisdiffusion might be one reason for the increased variability
seen. CCL2 protein was also measured in the subchondral
bone and fat pad and found to be significantly increased
compared to controls. This is in contrast to mRNA where
no significant increases were found. One worry with meas-
uring mRNA, particularly in this study, is that the large
increases found in mRNA expression would not be mir-
rored on the protein level. Here we find the opposite. For
the subchondral bone a strong trend for increased mRNA
was found for CCL2 at day 14 which narrowly failed to
reach statistical significance. However for the fat pad there
was no increase in CCL2 mRNA. The increase in CCL2
protein is most likely the result of CCL2 protein being
secreted into the fat pad from another tissue source.
Although these data do not directly correlate, we find that
on both an mRNA and protein level CCL2 is significantly
up-regulated in the MIA treated joint at day 14.
As mentioned, a number of chemokines have been im-
plicated in modulating pain processing and one possible
mechanism is via the recruitment of immune cells. Pre-
vious work has shown that blocking the effects of che-
mokines in inflammatory pain models can reduce both
neutrophil and macrophage infiltration and reduce pain-
related hypersensitivity [30,41]. CCL2, which has been
shown to have pro-nociceptive properties [14,42,43] can
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http://www.molecularpain.com/content/9/1/57recruit immune cells [44]. It seems that CCL2 is respon-
sible for macrophage recruitment into the injured nerve
[45] and neuropathic pain can be attenuated by reducing
their infiltration [46]. Therefore immune cells might con-
tribute to OA pain particularly in the early inflammatory
phase. Chemokines can also regulate the function of
immune-related cells. For example CCL9 and its receptor
CCR1 are the major chemokine ligand and receptor pair
expressed by osteoclasts [47]. Osteoclast numbers in-
crease in the later stages of the MIA model and their
activity is responsible for bone resorption [21,34]. It is
therefore intriguing that osteoclast activity has been im-
plicated in pain-like behaviour in the MIA model [34] as
well as in other pain models with bone pathology [48].
The contribution of immune cells to pain-related be-
haviours in the later stages of the MIA is unclear. At day
14 joint swelling has diminished, NSAIDs do not seem
to affect pain behaviours [22] and there is no infiltration
of immune cells. On the contrary, the increase in che-
mokine expression is still present and particularly in the
case of the cartilage, even greater. The resolution of in-
flammation is regulated by many factors and these might
act to prevent the action of chemokines on certain inflam-
matory cells. For example, one group of pro-resolving fac-
tors known as resolvins can act to prevent the expression
of certain chemokine receptors by immune cells [49], thus
preventing the ability of chemokines to recruit such cells.
Instead chemokines might now act via a direct mech-
anism to cause pain since a number of members have
been shown to induce calcium transients in cultured DRG
neurons [50]. Recently, in a mouse model of surgically-
induced OA, the increased expression of CCR2, the recep-
tor for CCL2, was found in DRG neurons and these cells
increased their responsiveness to ligand application
in vitro [51]. Similar findings have been seen in nerve-
injury models [52-55] and ATF3 expression is seen transi-
ently in the DRG after 1 mg of MIA [22]. More in depth
in vitro analysis has found that CCL2 can increase the ac-
tivity of the sodium channel subunit Nav1.8 in DRG neu-
rons [56] and Nav1.8 antagonists can reduce the firing
rate of joint afferents and pain-related behaviours in the
MIA model [57]. Therefore it seems possible that CCL2
produced in the joint could induce pain-related hypersen-
sitivity by the direct sensitisation of sensory fibres. In
agreement with both indirect and direct actions, CCR2
null mice do not develop movement induced pain follow-
ing surgical induction of OA [51].
As mentioned CCL9, the most up-regulated factor in
the highly innervated bone, acts through the CCR1 re-
ceptor [58]. The expression of this receptor has been
found on DRG neurons [59]. Ligands acting on this recep-
tor can either sensitise TRPV1 [59] or desensitise opioid
receptors [60], in this way helping to induce or maintain a
state of pain-related hypersensitivity. CCL7 was the topcombined ranked chemokine in terms of up-regulation in
the selected joint tissues of the MIA model. It is both simi-
lar in structure and function to CCL2 [61,62] and can also
act through CCR1. Therefore it would be particularly inter-
esting to see whether either CCL7 or CCL9 could act dir-
ectly by looking at acute calcium responses in cultured
DRG neurons from both naïve and MIA animals following
their application.
The greatest up-regulation in chemokines was found
in the cartilage at day 14 suggesting that a direct action
would be unlikely since the cartilage is devoid of sensory
nerve fibres. However, in OA patients progressive changes
within the joint allow sensory nerve fibres to innervate the
cartilage [15] and therefore chemokines produced by this
tissue could now act directly on these fibres to cause pain.
This innervation initially requires the vascularisation of
the cartilage and chemokines have a well-defined role
in angiogenesis [63] where blood vessels follow chemo-
tactic gradients to vascularise tissue. Therefore the an-
giogenic properties of chemokines might represent an
additional mechanism by which pain is facilitated in
OA, particularly since neurovascularisation of cartilage
as well as other articular tissues has been implicated in
causing OA pain [64].
Evidence from clinical studies suggests that the persistent
pain associated with OA has a strong peripheral compo-
nent, most likely as a result of mediators acting within the
affected joint. Here we show that many inflammatory fac-
tors are up-regulated in the MIA model, identifying them
as putative pain mediators of chronic joint pain. In particu-
lar, a group of chemokines were consistently up-regulated
and represent good targets for future studies in the devel-
opment of treatments for OA pain.Methods
Animals
Experiments were performed using male Wistar rats
(~250 g, Harlan) in accordance with the United Kingdom
Home Office Animals (Scientific Prodcedures) Act 1986.
Food and water was available ad libitum and animals were
housed under standard conditions with a 12 hour light/
dark cycle.MIA model induction
Animals were anaesthetised with 3.5% isoflurane and
subjected to a single intra-articular injection of 1 mg
MIA (Sigma) based on previous literature [22]. Prior to
injection, hair was removed from around the knee joint
and cleaned with the use of an alcohol wipe. Doses of
MIA were made up fresh in 20 μl of sterile physiological
saline solution and administered with the use of a
Hamilton syringe (Hamilton) through the infra-patellar
ligament into the left knee joint capsule. Control animals






18 s CTTAGAGGGACAAGTGGCG GGACATCTAAGGGCATCACA
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ile saline alone.
Behavioural testing
Weight bearing asymmetry was used as a measure of
primary pain-related hypersensitivity. The weight borne
on each hind limb was recorded with the use of an inca-
pacitance meter (Linton Instruments). Rats were placed
in a Perspex box and positioned so that their both hind
paws were placed on force transducer pads. Once ani-
mals were settled and in the correct position, a reading
of their weight distribution was taken. This reading was
averaged over a 3 second period and the output produced
an individual measurement of how much weight was
borne on the ipsilateral and contralateral hind limbs. This
method was repeated three times and the results aver-
aged for each time point. Results were calculated as the
percentage difference in weight distribution (Percentage
difference = (ipsilateral/contralateral) x 100). Animals were
trained for 1–2 weeks prior to MIA injections and baseline
readings were obtained. All behavioural testing was per-
formed blind.
Tissue dissection and RNA extraction
Fat pad, cartilage and subchondral bone (containing
underlying bone marrow) was removed from the femoroti-
bial joint of both MIA and vehicle treated animals at 3 and
14 days post intra-articular injection. Rats were terminally
anaesthetised and then transcardially perfused with cold
physiological saline (0.9% Sodium chloride in dH2O). Fol-
lowing hair removal, the skin was cut to expose the
femorotibial joint. The infrapatellar ligament, to which
the fat pad is attached, was cut at the femoral head and
dissected away from the joint capsule. Subsequently the
fat pad was separated from the ligament. The knee joint
capsule was opened by cutting the remaining cruciate
and collateral ligaments. Cartilage was carefully removed
from the tibial plateau and femoral condyles. The sub-
chondral bone was taken from the tibia. Once removed
each tissue was washed in sterile saline and snap frozen
in liquid nitrogen and stored at −80°C. Tissue samples
were then homogenised and total RNA obtained using a
‘hybrid’ method of phenol extraction (Trizol, Invitrogen)
and column purification (RNeasy, Qiagen). This helped
to achieve the extraction of high-quality RNA without a
significant drop in yield (all 260:280 ratios were in the
range of 1.94-2.12). All samples were DNase (Qiagen)
treated to prevent genomic contamination and an RNA
6000 Nano Chip (Agilent) was used to ensure sufficient
RNA integrity (RINs 7–10) and concentration was deter-
mined using a spectrophotometer (NanoDrop 1000).
RNA was subsequently synthesised into cDNA using the
Superscript II reverse transcriptase kit (Invitrogen) by fol-
lowing the manufacturer’s protocol.qPCR array cards and conventional qPCR
Taqman qPCR array cards were custom-made and de-
signed using the Applied Biosystem website (http://www.
appliedbiosystems.com). Each 384 well card contained 4
sets of 96 different primer pairs which included 4 refer-
ence genes (glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), 18 s, beta-actin and hypoxanthine phosphori-
bosyltransferase 1 (HPRT1)). For each tissue type, samples
contained cDNA from individual animals. Each cDNA
samples was diluted with polymerase chain reaction (PCR)
grade water and added in a 1:1 ratio to Taqman Universal
master mix producing a final concentration of 1 ng/μl.
Samples were fed into the appropriate loading ports (1 μl
for each well) and prepared according to the manu-
facturer’s guidelines. Cards were placed into a 7900HT
Fast Real-Time PCR system (Applied Biosystems). Ex-
pression of each transcript was measured using the delta
delta quantification cycle (2-ΔΔCq) method and analysis
was carried out using the ReadqPCR and NormqPCR R
packages [65]. Relative expression changes in transcript
levels are presented as a fold change (FC =MIA/Control).
Undetermined values were given a Cq (quantification
cycle) value of 38. However, for a given detector, if more
than 50% of samples were undetermined in both groups
no FC was calculated and the transcript was described as
undetected.
To measure the relative expression changes in immune
cell markers, individual reverse transcriptase quantitative
PCR was performed using the Corbett Rotor-Gene 6000.
Samples were processed in duplicate and amplified using
the Roche Lightcycler mastermix containing SYBR green
for the detection of real-time changes. Primers were de-
signed using Primer blast (Table 4) and the efficiency of all
primers was in the range of 0.8-1.2. Transcript levels were
again measured using the 2-ΔΔCq method normalised
against 18 s. The relative mRNA expression is shown as
the amount of transcript in the treated samples versus con-
trol. Primer sequences for both G-CSFR and IBA1 were
previously published [30].
Combined-ranking
Within each data set genes were ranked by FC, from the
most up-regulated to the most down-regulated when
compared to expression in control samples. The top
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number of all target genes), then next gene a value of
91 etc. The most down-regulated was given a value of 1
and those undetected genes were given a rank value of
0. To get an idea of gene regulation across different
data sets an average of rank values was calculated to
give a combined-rank value (CRV) for each gene. Genes
were then ordered by CRV to show which genes were
consistently up-regulated across tissues and time points
in the MIA model.
Protein extraction and ELISA
Tissue samples (cartilage, subchondral bone and fat pad)
were dissected as described above. Since the amount of
cartilage obtained at day 14 in the MIA is significantly re-
duced, samples were pooled in an effort to increase total
protein concentrations. Following storage at −80°C, each
tissue was washed and then homogenised in lysis buffer
(phosphate buffered saline (PBS), 12.5 mM ethlenediami-
netetraacetic (EDTA), 1:100 protease inhibitors (Sigma)).
EMPIGEN (Sigma) was added to the homogenate (0.2%).
Samples were then vortexed for 1 hour, centrifuged and
supernatants collected. Total protein concentration was
determined using a spectrophotometer (NanoDrop 1000).
The amount of CCL2 protein was quantified using the
Quantikine ELISA kit (R & D Systems) and by following
the manufacturer’s instructions. For each sample of each
tissue type 50 ul of neat lysate was used in duplicate
and CCL2 protein concentration was determined against
a standard curve. ELISA data is shown normalised to
1 mg/ml of the total protein loaded.
Statistical analysis
For Taqman array cards, statistical significance was calcu-
lated by running t-tests in R (two-sided, Welch’s t-test) on
the ΔCq values (ΔCq = gene of interest transcript Cq –
reference gene Cq). To control for multiple hypothesis
testing, the p values were adjusted using the FDR correc-
tion as proposed by Benjamini and Hochberg [66]. All
other statistical analysis was carried out using the Sigma-
Stat software. Where the data was not normally distrib-
uted and had unequal variance, the Mann–Whitney rank
sum test was used to compare groups.
Additional files
Additional file 1: Table S1. FC values for all inflammatory mediators
measured in Cartilage, Subchondral bone and fat pad at both day 3 and 14.
Additional file 2: Figure S1. Validation of CCL2 and CCL9 mRNA
expression up-regulation in the MIA model. Relative changes in the transcript
levels of CCL2 (A-C) and CCL9 (D-F) were measured in cartilage at day 3 and
14 (A&D and B&E, respectively) and subchondral bone at day 14 (C&F) in the
MIA model and compared to vehicle controls using conventional QPCR. No
significant increase was measured for CCL2 in the cartilage at day 3 (A) and
subchondral bone at day 14 (C). A significant increase was found in CCL2expression in the cartilage of MIA treated animals at day 14 compared to
controls (B). A significant increase in CCL9 expression was measured for
cartilage at day 3 and 14 and the subchondral bone at day 14 (D, E F). T –Test
(A, C, D, F), Mann–Whitney Rank Sum Test (B, E), *p < 0.05; n = 4. All data are
expressed as mean ± SEM.
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